Tumors of the heart are uncommon, and lymphangioma is one of the rarest forms of this pathologic process. We describe an asymptomatic patient whose tumor was detected incidentally during coronary artery bypass operation. We detected a spongiform thin-layered mass covering about one-third of the right ventricular epicardium. Excisional biopsy was performed, and the main operation continued. Cardiac lymphangiomas are rare tumors of the heart and mostly benign. In general, surgical excision is performed when it is diagnosed. We detected the lesion incidentally; for this reason, we took only an excisional biopsy specimen. After exact pathologic diagnosis, the patient was observed with routine medical follow-up.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2022.01.060DOI Listing

Publication Analysis

Top Keywords

tumors heart
8
excisional biopsy
8
ventricular epicardium-originated
4
epicardium-originated cardiac
4
cardiac lymphangioma
4
lymphangioma rare
4
rare tumor
4
tumor rare
4
rare origin
4
origin tumors
4

Similar Publications

Background: Cardiac rhabdomyoma (RHM) is considered one of the most frequent benign heart tumors in children. However, encounters with cardiac RHM in clinical practice remain rare. Clinical information is primarily available in the form of single case reports or smaller studies with a shortage of large-scale reviews encompassing a substantial number of cases.

View Article and Find Full Text PDF

Despite advances in precision oncology, clinical decision-making still relies on limited variables and expert knowledge. To address this limitation, we combined multimodal real-world data and explainable artificial intelligence (xAI) to introduce AI-derived (AID) markers for clinical decision support. We used xAI to decode the outcome of 15,726 patients across 38 solid cancer entities based on 350 markers, including clinical records, image-derived body compositions, and mutational tumor profiles.

View Article and Find Full Text PDF

The year 2024 has seen significant progress in the management of heart failure. New treatments have demonstrated their efficacy, particularly for heart failure with preserved ejection fraction, cardiac amyloidosis, and hypertrophic cardiomyopathy. Advances in imaging, such as MRI and PET-CT, highlight the growing integration of innovative technologies and artificial intelligence in cardiology for diagnosing complex cardiovascular diseases.

View Article and Find Full Text PDF

Role of PGC-1α in the proliferation and metastasis of malignant tumors.

J Mol Histol

January 2025

Department of Thoracic Surgery, Lung Cancer Diagnosis and Treatment Center of Dalian, The First Affiliated Hospital of Dalian Medical University, Dalian, 116011, China.

Malignant tumors are among the major diseases threatening human survival in the world, and advancements in medical technology have led to a steady increase in their detection rates worldwide. Despite unique clinical presentations across the spectrum of malignancies, treatment modalities generally adhere to common strategies, encompassing primarily surgical intervention, radiation therapy, chemotherapy, and targeted treatments. Uncovering the genetic elements contributing to cancer cell proliferation, metastasis, and drug resistance remains a pivotal pursuit in the development of novel targeted therapeutics.

View Article and Find Full Text PDF

Cardiomyocytes can be implanted to remuscularize the failing heart. Challenges include sufficient cardiomyocyte retention for a sustainable therapeutic impact without intolerable side effects, such as arrhythmia and tumour growth. We investigated the hypothesis that epicardial engineered heart muscle (EHM) allografts from induced pluripotent stem cell-derived cardiomyocytes and stromal cells structurally and functionally remuscularize the chronically failing heart without limiting side effects in rhesus macaques.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!